Continuus Pharmaceuticals has secured a $69.3M contract with the Department of Defense to use its integrated continuous manufacturing technology for developing critical active pharmaceutical ingredients and final dosage form medicines used for COVID-19 treatment.
The company will employ the ICM, a fully-automated, small-footprint facility, to provide the U.S. with domestic production capability in support of caring for COVID-19 patients, DOD said Friday.
The U.S. currently sources critical APIs and their starting materials from companies outside the country.
With the investment, Continuus will enable onshore manufacturing of three critical APIs and their final dosage forms. The company will also use the ICM technology to streamline logistical processes for future health care needs.
DOD issued the contract in coordination with the Department of Health and Human Services and under the Coronavirus Aid, Relief, and Economic Security Act.